South San Francisco, CA, United States of America

Rohan V Mendonca

This inventor holds 16 USPTO granted patents and 12 published patent applications and 11 EPO patents. Top assignees: Genentech, Inc., Newlink Genetics Corporation, Axys Pharmaceuticals, Inc.. Active years: 2003-2026.

USPTO Granted Patents = 16 (Patent Applications = 12)

% Patents Active = 87.5

EPO Patents = 11 (Patent Applications = 12)

Average Co-Inventor Count = 11.9

ph-index = 3

Forward Citations = 61(Granted Patents)

Location History:

Millbrae, CA (US) (2003)
South San Francisco, CA (US) (2003 - 2023)
Pleasanton, CA (US) (2013 - 2023)

Company Filing History:

Newlink Genetics Corporation

patents

1 out of 40

Axys Pharmaceuticals, Inc.

where one patent can have more than one assignee

Years Active: 2003-2026

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12583858 - TDO2 inhibitors (2026-03-24),

2. 12473301 - Isoquinoline compounds for the treatment of cancer (2025-11-18),

3. 12378249 - Isoquinoline compounds and uses thereof (2025-08-05),

4. 12297210 - Naphthyridine compounds and uses thereof (2025-05-13),

5. 11612606 - 8-aminoisoquinoline compounds and uses thereof (2023-03-28),

6. 11603373 - TDO2 and IDO1 inhibitors (2023-03-14),

7. 11566003 - Isoquinolines as inhibitors of HPK1 (2023-01-31),

8. 11034692 - Naphthyridines as inhibitors of HPK1 (2021-06-15),

9. 10800780 - TDO2 Inhibitors (2020-10-13),

10. 10407424 - Naphthyridines as inhibitors of HPK1 (2019-09-10),

11. 9604984 - 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds, compositions and methods of use thereof (2017-03-28),

12. 9346815 - 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds, compositions and methods of use thereof (2016-05-24),

13. 8999998 - Pyrazolopyrimidine JAK inhibitor compounds and methods (2015-04-07),

14. 8461328 - Tricyclic heterocyclic compounds, compositions and methods of use thereof (2013-06-11),

15. 6525036 - Compounds and compositions as protease inhibitors (2003-02-25),

Title: Rohan V Mendonca: Innovator in Cancer Treatment

Introduction

Rohan V Mendonca is a prominent inventor based in South San Francisco, CA. He has made significant contributions to the field of cancer treatment through his innovative research and development of isoquinoline compounds. With a total of 16 patents to his name, Mendonca's work is paving the way for new therapeutic approaches in medicine.

Latest Patents

Mendonca's latest patents focus on isoquinoline compounds that are designed for the treatment of cancer. One of his notable inventions is the 3-Carbonylaminoisoquinoline compounds, which serve as inhibitors of HPK1 (hematopoietic kinase 1). These compounds are particularly useful in treating HPK1-dependent disorders and enhancing immune responses. His patents also describe various methods for inhibiting HPK1, treating related disorders, and preparing these innovative compounds.

Career Highlights

Throughout his career, Rohan V Mendonca has worked with leading companies in the pharmaceutical industry, including Genentech, Inc. and Axys Pharmaceuticals, Inc. His experience in these organizations has allowed him to collaborate with some of the brightest minds in the field, further enhancing his contributions to cancer research.

Collaborations

Mendonca has had the opportunity to work alongside esteemed colleagues such as Lewis J Gazzard and Michael Siu. These collaborations have played a crucial role in advancing his research and expanding the impact of his inventions.

Conclusion

Rohan V Mendonca is a dedicated inventor whose work in developing isoquinoline compounds is making a significant impact in the fight against cancer. His innovative approaches and collaborations continue to inspire advancements in medical research and treatment options.